Product Comparison


 
Glaxo Specialty 49401008847

No Image
Strides Pharma 64380072106
Teva 00172731320
NorthStar Rx 16714018801
McKesson # 1184513 1176906 1178419 740107 1210971
Description Benlysta® Belimumab 200 mg / mL Injection 4 per Box Azathioprine 50 mg Tablet 100 Tablets Tacrolimus 1 mg Capsule 100 Capsules Cyclosporine, Modified 100 mg / mL Solution 50 mL Sirolimus 1 mg Tablet 100 Tablets
Manufacturer # 4940100884767877049301643800721060017273132016714018801
Brand Benlysta®    
Manufacturer Glaxo SpecialtyAscend LaboratoriesStrides PharmaTevaNorthStar Rx
Invoice BENLYSTA, SYR 200MG/ML (4/BX)AZATHIOPRINE, TAB 50MG (100/BT)TACROLIMUS, CAP 1MG (100/BT)CYCLOSPORINE, SOL 100MG/ML 50MLSIROLIMUS, TAB 1MG (100/BT)
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison
Alternate Manufacturer Number 1539089343651616439722358448
Container Type Prefilled SyringeBottleBottleBottleBottle
Dosage Form InjectionTabletCapsuleSolutionTablet
Generic Drug Code 46771284911391713696
Generic Drug Name BelimumabAzathioprineTacrolimusCyclosporine, ModifiedSirolimus
NDC Number 4940100884767877049301643800721060017273132016714018801
Product Dating McKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 days
Quantity 4 per Box100 Tablets100 Capsules100 Tablets
Storage Requirements Requires Refrigeration
Strength 200 mg / mL50 mg1 mg100 mg / mL1 mg
Type SubcutaneousOral
UNSPSC Code 5120240351203401512028045120310151202803
Volume 50 mL
Application Immunosuppressive AgentImmunosuppressive AgentImmunosuppressive AgentImmunosuppressive AgentImmunosuppressive Agent
Country of Origin UnknownUnknownUnknownUnknownUnknown
Features and Benefits
  • BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy
  • BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: adult patients with active lupus nephritis who are receiving standard therapy.
  • BENLYSTA (belimumab) injection is a clear to opalescent, and colorless to pale yellow solution for subcutaneous use. Each single-dose prefilled syringe is designed to deliver 200 mg of belimumab in 1 mL of solution and is supplied as follows: 200 mg/mL single-dose prefilled glass syringe with 27-gauge, half-inch needle attached in a carton of 4 (NDC 49401-088-47).
  • Requires Refrigeration